Lower Blood Glucose when Using Remote Diabetes Care System with Patient App

Using the Triabetes® smartphone app and TriabetesClinic online decision support service in Type 2 diabetes treatment helps reduce long-term blood glucose levels. This is the main finding reported by Professor Kerstin Brismar from Karolinska Institutet in Stockholm.

Results from the first six months of a two-year randomized, multicenter clinical study show that the blood glucose marker HbA1c is significantly lower in patients being managed by the TriabetesClinic system compared with the control group who is not.

The research, presented during a seminar for delegates at the meeting of the Swedish Society for Diabetology, aims to detect a minimum 5.5 mmol/mol decrease in HbA1c in the patients who self-report to the healthcare provider's remote care system using a smartphone app across four different treatment clinics over 24 months. Intention-to-treat analysis was applied to the interim results which show a significant median difference of 5.3 mmol/mol between the smartphone app and control groups during just six months.

"We found that it is clinically worthwhile to use the Triabetes app combined with the TriabetesClinic service to support the patients to improve metabolic control and lower their HbA1c values," said Kerstin Brismar, Professor of diabetes research at Karolinska Institutet. "Our analysis after six months showed that apps are a viable way to help control type 2 diabetes when the patient shares live data with their doctor or nurse, who in turn use a web-based triage service to monitor, coach and suggest treatment strategies."

"I welcome today's interim results since there are few rigorous studies that report on the clinical use of telemedicine systems in diabetes management," said Diabetes Tools' Chief Executive Officer Anders Weilandt.

There are 226 patients with Type 2 diabetes taking part in the study. They are spread across nine different primary care clinics in Poland run by the managed care group Medicover. The study uses medtech firm Diabetes Tools' Triabetes smartphone app for patients and TriabetesClinic, a web-based diabetes decision support service, for healthcare providers. This research is backed by academics from the Medical University of Warsaw and Karolinska Institutet in Stockholm, Sweden.

About Triabetes and Diabetes Tools
Triabetes is a smartphone app and online decision support service for people living with and caring for all forms of diabetes. Triabetes is from Diabetes Tools, a Swedish medical technology company that develops scientifically based Software-as-a-Service solutions. Triabetes is scalable. It can be used by individuals, doctors and treatment clinics, and can be integrated with large-scale Electronic Medical Record (EMR) systems.

Founded in 2005, Diabetes Tools is a privately held company located in Stockholm, Sweden. Diabetes Tools holds an ISO 13485 certificate, a compliance standard for creating medical devices and related services. Triabetes is a CE-marked medical software product registered for sale in the European Union. More information at http://www.diabetestools.se.

Most Popular Now

MEDICA 2024 + COMPAMED 2024: Adapted Hal…

11 - 14 November 2024, Düsseldorf, Germany. The final preparations for MEDICA 2024 and COMPAMED 2024 in Düsseldorf have begun. A total of more than 5,500 exhibitors from approximately 70 countries...

AI does Not Necessarily Lead to more Eff…

The use of artificial intelligence (AI) in hospitals and patient care is steadily increasing. Especially in specialist areas with a high proportion of imaging, such as radiology, AI has long...

Commission Joins Forces with Venture Cap…

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment...

Why the NHS is Seeking to Make Media Ser…

Opinion Article by Dean Moody, Healthcare Services Director, Airwave Healthcare. Tim Kelsey and Martha Lane Fox called for WiFi to be made available free of charge throughout the NHS back in...

An AI-Powered Pipeline for Personalized …

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

AI could Transform How Hospitals Produce…

A pilot study led by researchers at University of California San Diego School of Medicine found that advanced artificial intelligence (AI) could potentially lead to easier, faster and more efficient...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

Great Start for Ideas and Innovations: D…

8 - 10 April 2025, Berlin, Germany. From 15 October to 15 November 2024, the DMEA invites experts from business, science, politics and practice to actively participate in shaping the congress...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...